Table 2.
Characteristics of the included studies in meta-analysis.
| Age (years) | Number of patients | Intervention drugs | Percentage of symptom improvement | |||||||||
| Study | Diagnostic criteria | Control group | Treatment duration | Case | Control | Case | Control | Case | Control | Case | Control | Adverse event |
| Cai et al (2016)[9] | RIIIC/CDTC | Prokinetic agents | 1 mo | 49.11 ± 6.48 | 48.76 ± 6.24 | 34 | 34 | MRCT(TID) | Mosapride (5 mg, TID) | 94.12% (32/34) | 79.41% (27/34) | Included |
| Chen et al (2014)[10] | DESS | Prokinetic agents | 10 d | 72.3 ± 2.45 | 74.2 ± 2.13 | 50 | 50 | MRCT(BID) | Cisapride (5 mg, BID) | 92% (46/50) | 82% (41/50) | Included |
| Deng et al (2015)[11] | DESS | Osmotic laxatives | 15 d | 54-70 | 54-70 | 50 | 50 | MRCT(BID) | Lactulose Oral Solution (10 g, SO, bid) | 96.00% (48/50) | 92.00% (46/50) | NR |
| Fang et al (2017)[12] | RIIIC/ CGND | Osmotic laxatives | 28 d | 45.30 ± 6.71 | 43.56 ± 6.81 | 31 | 29 | MRCT(BID) | Macrogol 4000 Powder (10 g, BID) | 97% (30/31) | 79% (23/29) | Included |
| Han (2015)[13] | RIIIC/ CGND | Osmotic laxatives | 3 wk | 57.6 ± 11.6 | 60.8 ± 10.2 | 56 | 56 | MRCT(BID) | Macrogol 4000 Powder (10 g, BID) | 96.43% (54/56) | 82.14% (46/56) | Included |
| Hou et al (2014)[14] | RIIIC/ DESS | Prokinetic agents | 4 wk | 43.28 ± 8.51 | 42.36 ± 8.13 | 30 | 30 | MRCT(BID) | Mosapride (5 mg, TID) | 90% (27/30) | 76.67% (23/30) | NR |
| Jiang (2016)[15] | GDTC | Stimulant laxatives | 8 wk | 65-78 | 65-78 | 32 | 32 | MRCT(BID) | Phenolphthalein (100 mg, BID) | 90.63% (29/32) | 75% (24/32) | NR |
| Li (2009)[16] | RIIIC/ CGND | Stimulant laxatives | 4 wk | 56.26 ± 8.81 | 57.45 ± 8.41 | 34 | 31 | MRCT(BID) | Bisacodyl Enteric-coated Tablets (10 mg, QN) | 79.41% (27/34) | 74.19% (23/31) | Included |
| Li et al (2013)[17] | DESS | Prokinetic agents | 2 wk | 50-72 | 50-72 | 30 | 30 | MRCT(BID) | Mosapride (5 mg, TID) | 93.33% (28/30) | 66.67% (20/30) | NR |
| Lu et al (2011)[18] | GDTC | Stimulant laxatives | 2 wk | 62-78 | 60-75 | 25 | 25 | MRCT(BID) | Phenolphthalein (100 mg, QN) | 92.00% (23/25) | 68.00% (17/25) | NR |
| Ren (2014)[19] | RIIIC/ CDTC | Osmotic laxatives | 8 wk | 43.6 ± 11.63 | 42.7 ± 11.05 | 30 | 30 | MRCT(BID) | Macrogol 4000 Powder (20 g, QD) | 86.7% (26/30) | 90% (27/30) | Included |
| Shi et al (2008)[20] | RIIIC | Osmotic laxatives | 4 wk | 32-68 | 30-66 | 30 | 30 | MRCT(BID) | Macrogol 4000 Powder (10 g, BID) | 96.7% (29/30) | 80% (24/30) | NR |
| Song et al (2007)[21] | RIIC | Prokinetic agents | 4 wk | 26-62 | 24-60 | 36 | 36 | MRCT(BID) | Cisapride (3 mg,TID) | 97.2% (35/36) | 88.89% (32/36) | NR |
| Sun (2007)[22] | RIIIC/DTSS | Prokinetic agents | 1 mo | 16∼68 | 16∼68 | 100 | 100 | MRCT(BID) | Mosapride (10 mg,TID) | 88% (88/100) | 58% (58/100) | NR |
| Tang et al (2009)[23] | RIIIC/ CGND | Osmotic laxatives | 4 wk | 42.75 ± 13.98 | 44.59 ± 15.80 | 51 | 49 | MRCT(BID) | Macrogol 4000 Powder (10 g, BID) | 96.08% (49/51) | 79.59% (39/49) | NR |
| Wan et al (2016)[24] | GDTC | Osmotic laxatives | 3 wk | 62.00 ± 3.50 | 64.00 ± 4.10 | 45 | 45 | MRCT(BID) | Lactulose Oral Solution (10 g, SO, bid) | 97.78% (44/45) | 80.00% (36/45) | NR |
| Wang (2004)[25] | DESS | Prokinetic agents | 3 wk | 20-52 | 18-50 | 36 | 30 | MRCT(BID) | Cisapride (10 mg, TID) | 91.7% (33/36) | 73.3% (22/30) | NR |
| Wei (2016)[26] | RIIIC/ CGND | Osmotic laxatives | 1 mo | 69.67 ± 5.63 | 70.00 ± 5.62 | 30 | 30 | MRCT(BID) | Macrogol 4000 Powder (10 g, BID) | 93.33% (28/30) | 73.33% (22/30) | Included |
| Wu (2013)[27] | RIIIC/ CGND | Osmotic laxatives | 4 wk | 59.97 ± 8.84 | 60.90 ± 9.58 | 30 | 30 | MRCT(BID) | Macrogol 4000 Powder (10 g, BID) | 93.33% (28/30) | 73.33% (22/30) | Included |
| Xin et al (2014)[28] | RIIIC/DESS | Stimulant laxatives | 4 wk | 68.2 ± 7.5 | 70.7 ± 8.7 | 35 | 35 | MRCT(BID) | Phenolphthalein (100 mg, QN) | 94.3% (33/35) | 80.0% (28/35) | NR |
| Xu (2010)[29] | GDTC | Prokinetic agents | 30 d | >60 | >60 | 80 | 50 | MRCT(QD) | Mosapride (10 mg, TID) | 93.75% (75/80) | 70% (35/50) | NR |
| Yang (2010)[30] | RIIIC | Prokinetic agents | 3 wk | 46.62 ± 8.93 | 45.95 ± 9.12 | 47 | 47 | MRCT(BID) | Mosapride (5 mg, TID) | 89.4% (42/47) | 76.6% (36/47) | NR |
| Yang et al (2017)[31] | RIIIC/ CDTC | Osmotic laxatives | 4 wk | 25-76 | 25-76 | 30 | 30 | MRCT(BID) | Lactulose Oral Solution (6.67 g, SO, TID) | 93.3% (28/30) | 76.7% (23/30) | NR |
| Zhang (2015)[32] | RIIC | Stimulant laxatives | 4 wk | 43.06 ± 9.67 | 42.38 ± 10.41 | 41 | 41 | MRCT(BID) | Phenolphthalein (200 mg, QN) | 92.70% (38/41) | 75.60% (31/41) | NR |
| Zhang (2018)[33] | RIIIC/CDTC | Prokinetic agents | 4 wk | 45.76 ± 5.07 | 46.01 ± 5.12 | 38 | 38 | MRCT(TID) | Mosapride (5 mg, TID) | 94.74% (36/38) | 78.95% (30/38) | NR |
| Zhao (2011)[34] | RIIC | Prokinetic agents | 3 wk | 62-81 | 60-84 | 42 | 42 | MRCT(BID) | Mosapride (10 mg, BID) | 88% (37/42) | 76% (32/42) | Included |